UNIVERSITY OF MASSACHUSETTS AMHERST
Designing a targeted 'super adjuvant' nanoparticle platform for vaccination
Designing a targeted 'super adjuvant' nanoparticle platform for vaccination is a funding opportunity from UNIVERSITY OF MASSACHUSETTS AMHERST, up to 200126, closing June 30, 2027.
Jun 30, 2027
(334d left)Overview
PROJECT SUMMARY This proposal seeks to develop a targeted tri-agonist “super adjuvant” nanoparticle platform for in situ cancer vaccination. Vaccines consist of 2 components: a tumor-specific antigen that is recognized by CD8+ cytotoxic T cells (CTLs) and an adjuvant that provides the necessary costimulatory…